VWF and Menorrhagia: In parallel, adjunctive therapies play a critical role in the management of non-severe mucocutaneous bleeding: desmopressin (DDAVP) reduces bleeding in uremia, aspirin-induced platelet dysfunction, and in cases of acquired mild storage pool deficiencies by enhancing the release of von Willebrand factor (VWF) and promoting platelet adhesion (108); tranexamic acid is an antifibrinolytic agent that reduces mucosal bleeding in dental procedures or menorrhagia; and local hemostatic measures like fibrin sealants and topical thrombin.